Premium
Methylation of breast cancer susceptibility gene 1 ( BRCA1 ) predicts recurrence in patients with curatively resected stage I non–small cell lung cancer
Author(s) -
Harada Hiroaki,
Miyamoto Kazuaki,
Yamashita Yoshinori,
Nakano Kikuo,
Taniyama Kiyomi,
Miyata Yoshihiro,
Ohdan Hideki,
Okada Morihito
Publication year - 2013
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.27754
Subject(s) - methylation , medicine , oncology , breast cancer , lung cancer , stage (stratigraphy) , cancer , proportional hazards model , hazard ratio , biomarker , dna methylation , adjuvant therapy , gene , biology , gene expression , confidence interval , paleontology , biochemistry
BACKGROUND: Even after early detection and curative resection of early stage non–small cell lung cancer (NSCLC), a significant fraction of patients develop recurrent disease. Molecular biomarkers that can predict the risk of recurrence thus need to be identified to improve clinical outcomes. METHODS: Using the methylation‐specific polymerase chain reaction assay, promoter methylation of the breast cancer susceptibility gene 1 ( BRCA1 ) was assessed in cancer tissues from 70 patients with curatively resected stage I NSCLC. The clinical relevance of BRCA1 methylation status was evaluated in terms of outcome of the disease. RESULTS: Methylation of the BRCA1 promoter was detected in 13 of 70 patients (18.6%). Multiple logistic regression analysis revealed that BRCA1 methylation was an independent risk factor for recurrence ( P = .0197) and that patients with BRCA1 methylation demonstrated significantly poorer recurrence‐free survival compared to those without ( P = .0139). Cox's proportional hazard regression analysis revealed that BRCA1 methylation was an independent risk factor for recurrence‐free survival ( P = .0155). CONCLUSIONS: Methylated BRCA1 can be a potential biomarker that predicts the prognosis after curative resection of stage I NSCLC. Considering that BRCA1 plays a role in chemotherapy‐induced apoptosis, it is plausible that identification of methylated BRCA1 could provide information that is clinically relevant to tailored adjuvant therapy. Cancer 2013. © 2013 American Cancer Society.